Age verification
Are you 21 or older?
This site features cannabis products. Please confirm your age before entering.
Age verification
This site features cannabis products. Please confirm your age before entering.
Cannabinol (CBN) has become increasingly popular in cannabis products marketed for nighttime use and sleep. You may have seen CBN described as a “sleep cannabinoid,” but how much of that claim is actually supported by research?
The answer is becoming more interesting. Early research was limited, but newer human studies are beginning to provide evidence that CBN may influence some aspects of sleep. However, the research is still too limited to consider CBN a proven treatment for insomnia. (PubMed Central (PMC))
CBN is a minor cannabinoid that can form as THC undergoes oxidation and degradation over time. Its association with sleep partly comes from the long-standing idea that older cannabis may have more sedating effects.
CBN products are therefore commonly marketed for nighttime use, relaxation, and sleep. However, marketing claims historically moved faster than the scientific evidence. A 2021 review found that clinical research specifically examining CBN and sleep was scarce, with much of the available human research dating back to the 1970s and 1980s. (PubMed Central (PMC))
For many years, there wasn’t enough high-quality human research to determine whether CBN itself could meaningfully improve sleep.
A 2021 review examined 99 human CBN studies and identified only eight full-text studies that met its criteria for detailed review. The review found that studies specifically measuring sleep with validated questionnaires or laboratory sleep testing were lacking. The authors concluded that there wasn’t sufficient clinical evidence at the time to support strong claims that CBN promotes sleep. (PubMed Central (PMC))
This is an important distinction:
CBN was widely discussed as a sleep cannabinoid, but the early clinical evidence didn’t establish that claim.
More recent research has started to change the conversation.
A 2026 randomized, double-blind, placebo-controlled crossover trial studied CBN in 20 adults with physician-diagnosed insomnia. Participants received either 30 mg CBN, 300 mg CBN, or a placebo on separate nights while researchers monitored their sleep using polysomnography. (PubMed)
The study found that:
Neither 30 mg nor 300 mg CBN significantly reduced wake time after initially falling asleep, which was the study’s primary outcome.
The 300 mg dose was associated with less time needed to fall asleep.
The 300 mg dose also increased subjective sleep quality.
Some measures of sleep activity and arousal were also improved.
Researchers did not find compelling evidence of a next-day “hangover” effect.
The study reported 247 mild-to-moderate adverse events across the treatment arms. (PubMed)
The researchers emphasized that larger and longer studies are still needed and that the findings do not establish CBN as an effective routine treatment for insomnia. (PubMed Central (PMC))
This is especially important for consumers because the doses used in clinical research don’t necessarily match the amounts found in everyday CBN products.
The 2026 insomnia study tested 30 mg and 300 mg, while many commercial CBN products contain considerably smaller amounts.
Therefore, you shouldn’t assume that a small amount of CBN in a consumer product will produce the same results observed in a clinical study. Dose, formulation, individual factors, and the presence of other cannabinoids can all matter.
CBN is also frequently combined with other cannabinoids or ingredients in products marketed for sleep.
A 2024 randomized, double-blind, placebo-controlled trial tested hemp-derived CBN formulations containing 25 mg, 50 mg, or 100 mg CBN and compared them with placebo and 4 mg melatonin. The study reported improvements in sleep-quality scores across the CBN groups and melatonin group compared with placebo, with no significant differences between the CBN formulations and melatonin. (PubMed Central (PMC))
However, studies of combination products or proprietary formulations don’t necessarily tell us what CBN alone does. This is one reason researchers continue to call for controlled studies of isolated CBN.
This is where it’s useful to be careful with terminology.
There is growing evidence that CBN may influence certain measures of sleep, but that is different from proving that CBN is a reliable sedative or insomnia treatment.
The newest clinical trial found improvements in several sleep measures at 300 mg, but its primary measure—wake after sleep onset—did not significantly improve. (PubMed)
So the current evidence is better described as:
CBN is a promising area of sleep research, but it is not yet a proven sleep medication.
It’s also important not to assume that research on cannabis or THC automatically applies to CBN.
Cannabis products can contain THC, CBD, CBN, or combinations of cannabinoids, and their effects on sleep can differ.
Recent systematic reviews of cannabinoids and sleep have found some evidence that cannabinoid treatments can improve subjective sleep quality, but the studies involve different cannabinoid formulations and cannot be used to conclude that CBN alone is responsible for those effects. (PubMed)
This distinction is particularly important when reading cannabis product marketing.
CBN is being actively studied for its potential effects on sleep.
Older research was limited and insufficient to support strong sleep claims.
Newer human research has found improvements in some sleep measures.
A 2026 randomized trial found that 300 mg CBN improved several sleep-related measures but did not significantly improve its primary outcome.
More research is needed to understand repeated use, long-term effects, and appropriate dosing. (PubMed Central (PMC))
Researchers still need to determine:
Whether CBN consistently improves sleep across larger populations.
Which doses are most appropriate.
Whether benefits continue with repeated use.
How CBN affects different types of insomnia.
How CBN interacts with THC, CBD, and other cannabinoids.
Whether improvements seen in controlled studies translate to everyday CBN products.
CBN and sleep is an area of growing scientific interest, but the research is still developing.
Older research did not provide enough evidence to support strong claims about CBN as a sleep aid. Newer clinical research is more encouraging, with one 2026 randomized trial finding that a 300 mg dose improved several subjective and objective sleep measures, although it did not improve the study’s primary outcome. (PubMed)
For consumers, the takeaway is simple: CBN may have sleep-related potential, but it should not be presented as a proven treatment for insomnia. More large-scale, long-term human studies are needed before researchers can determine how effective CBN is, which doses are appropriate, and who is most likely to benefit.
